Atopic Dermatitis / Eczema Clinical Trials

Currently Enrolling

Phoenix, Arizona Clinical Trials:
  • Corrona Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness. Any adult patient who has started a biologic therapy in the past year, or is being prescribed a biologic therapy by one of our dermatologists, is eligible! (Clinical Trial Conducted in Phoenix, Arizona – 7th Street Location)  |  Learn More »

  • DermTech Protocol 20-03: A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in Pediatric and Adult Patients with Atopic Dermatitis (Clinical Trial Conducted in Phoenix, Arizona – 7th Street Location)  |  Established Patients Only

 

Rockville, Maryland Clinical Trials:
  • Regeneron Protocol R668-AD-1762: A prospective observational study of adult patients receiving Dupixent® for atopic dermatitis. For patients 12 years and older. (Clinical Trial Conducted in Rockville, Maryland)  |  Learn More »  |  Request to Join This Study »

  • Corrona Protocol AD-550: A Phase 4 observational study that compares systemic atopic dermatitis therapies that are available for prescription. (Clinical Trial Conducted in Rockville, Maryland)   |  Learn More »  |  Request to Join This Study »

  • Regeneron R668-AD-1924: A multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of dupilumab in adult and adolescent patients with moderate-to-severe atopic hand and foot dermatitis. (Clinical Trial Conducted in Rockville, Maryland)   |  Learn More »  |  Request to Join This Study »

  • Target-Derm: A 5-year longitudinal observational study of patients undergoing therapy for immune-mediated inflammatory skin condition. (Clinical Trial Conducted in Rockville, Maryland)   |  Learn More »  |  Request to Join This Study »

 

Active / Not Enrolling

Phoenix, Arizona Clinical Trials:
  • AbbVie Protocol M18-891: A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2). (Clinical Trial Conducted in Phoenix, Arizona – 7th Street Location) | Learn More »  |  No Longer Enrolling

 

Rockville, Maryland Clinical Trials:
  • Lilly protocol I4V-MC-JAIX: A multicenter, open-label, Phase 3 Study to evaluate the efficacy and safety of Baricitinib in adult patients with moderate-to-severe atopic dermatitis. (Clinical Trial Conducted in Rockville, Maryland) | Learn More »  |  No Longer Enrolling

  • Pfizer Protocol B7451015: A Phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate-to-severe atopic dermatitis.  (Clinical Trial Conducted in Rockville, Maryland)  |  Learn More »  |  No Longer Enrolling

  • Abbvie Protocol M16-813: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate Risankizumab in adult and adolescent subjects with moderate-to-severe atopic dermatitis.  (Clinical Trial Conducted in Rockville, Maryland)  |  Learn More »  |  No Longer Enrolling

  • Regeneron Protocol R668-AD-1539 Part B: A Phase 2/3 study investigating the Pharmacokinetics, safety, and efficacy of a biologic IL-4 inhibitor (Dupilumab) in patients aged ≥6  months to <6 years. (Clinical Trial Conducted in Rockville, Maryland)  |  Learn More »  |  No Longer Enrolling

  • Dermira Protocol DRM06-AD06: A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab (a biologic IL-13 inhibitor) when used in combination with topical corticosteroid treatment in patients with moderate-to-severe atopic dermatitis. For patients 12 years of age or older. (Clinical Trial Conducted in Rockville, Maryland)   |  Learn More »  |  No Longer Enrolling

  • Dermira Protocol DRM06-AD17: A Phase 3, open-label, single-arm study to assess the safety and efficacy of Lebrikizumab (a biologic IL-13 inhibitor) in adolescent patients with moderate-to-severe atopic dermatitis. For patients 12 through 17 years old. (Clinical Trial Conducted in Rockville, Maryland)  |  Learn More »  |  No Longer Enrolling

  • Sanofi Protocol OBS15333: Prospective, observational, longitudinal study in pediatric patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable. For children up to age 11. (Clinical Trial Conducted in Rockville, Maryland)  |  Learn More »  |  No Longer Enrolling

 

View Other Clinical Trials